Transformation of human bronchial epithelial cells alters responsiveness to inflammatory cytokines

BMC Cancer

Volumn 5, Issue , 2005, Pages

  Loewen, Gregory M ^a   Tracy, Erin ^a   Blanchard, Frédéric ^a   Tan, Dongfeng ^a   Yu, Jihnhee ^a   Raza, Sameera ^a   Matsui, Sei Ichi ^a   Baumann, Heinz ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; MACROPHAGE DERIVED CHEMOKINE; MITOGEN ACTIVATED PROTEIN KINASE; ONCOSTATIN M; STAT PROTEIN; HISTONE; OSM PROTEIN, HUMAN;

ARTICLE; BRONCHUS BIOPSY; BRONCHUS MUCOSA; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CELL TRANSFORMATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; EPIGENETICS; EPITHELIUM CELL; HUMAN; HUMAN CELL; LUNG CANCER; LUNG CARCINOGENESIS; MALIGNANT TRANSFORMATION; PRECANCER; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; CELL CULTURE; CELL LINE; CYTOLOGY; DENSITOMETRY; FIBROBLAST; INFLAMMATION; LUNG; LUNG TUMOR; MACROPHAGE; METABOLISM; PATHOLOGY; TIME; TREATMENT OUTCOME; TUMOR CELL LINE;

CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CYTOKINES; DENSITOMETRY; EPIDERMAL GROWTH FACTOR; EPITHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLASTS; HISTONES; HUMANS; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-6; LUNG; LUNG NEOPLASMS; MACROPHAGES; ONCOSTATIN M; SIGNAL TRANSDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 27844525518     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-5-145     Document Type: Article

References (38)

1. Driscoll KE, Carter JM, Howard BW, Hassenbein DG, Pepelko W, Baggs RB, Oberdorster G: Pulmonary inflammatory, chemokine, and mutagenic responses in rats after subchronic inhalation of carbon black. Toxicol Appl Pharmacol 1996,136:372-380.
2. Ardies CM: Inflammation as cause for sear cancers of the lung. Integr Cancer Ther 2003, 2:238-246.
3. Philip M, Rowley DA, Schreiber H: Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 2004, 14:433-439.
4. S Lam, T Kennedy, M Unger, YE Miller, D Gelmont, V Rusch, B Gipe, D Howard, JC, LeRiche, A Coldman and AF Gazdar: Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. Chest 1998, 113:696-702.
5. Saccomanno G, Archer VE, Auerbach O, Saunders RP, Brennan LM: Development of carcinoma of the lung as reflected in exfoliated cells. Cancer 1974, 33:256-270.
6. Auerbach O, Saccomanno G, Kuschner M, Brown RD, Garfinkel L: Histologic findings in the tracheobronchial tree of uranium miners and non-miners with lung cancer. Cancer 1978, 42:483-489.
7. Bota S, Auliac JB, Paris C, Metayer J, Sesboue R, Nouvet G, Thiberville L: Follow-up of bronchial precancerous lesions and carcinoma in situ using fluorescence endoscopy. Am J Respir Crit Care Med 2001, 164:1688-1693.
8. Hirsch FR, Prindiville SA, Miller YE, Franklin WA, Dempsey EC, Murphy JR, Bunn PA Jr, Kennedy TC: Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: a randomized study. J Natl Cancer Inst 2001, 93:1385-1391.
9. Breuer RH, Pasic A, Smit EF, van Vliet E, Vonk Noordegraaf A, Risse EJ, Postmus PE, Sutedja TG: The natural course of preneoplastic lesions in bronchial epithelium. Clin Cancer Res 2005, 11:537-543.
10. Knaapen AM, Borm PJ, Albrecht C, Schins RP: Inhaled particles and lung cancer. Part A: Mechanisms. Int J Cancer 2004, 109:799-809.
11. Emmendoerffer A, Hecht M, Boeker T, Mueller M, Heinrich U: Role of inflammation in chemical-induced lung cancer. Toxicol Lett 2000; 112-113: 185-191.
12. Grant SL, Begley CG: The oncostatin M signalling pathway: reversing the neoplastic phenotype? Mol Med Today 1999, 5:406-412.
13. Kortylewski, M, Heinrich PC, Mackiewicz A, Schniertshauer U, Klingmuller U, Nakajima K, Hirano T, Horn F, Behrmann I: Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1. Oncogene 1999, 18:3742-3753.
14. Heinrich PC, Behrmann I. Haan S, Hermanns HM, Muller-Newen G, Schaper F: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003, 374:1-20.
15. Kim H, Baumann H: Dual signalling role of the protein tyrosine phosphatase SHP-2 in regulating expression of acute-phase plasma proteins by interleukin-6 cytokine receptors in hepatic cells. Mol Cell Biol 1999, 19:5326-5338.
16. Blanchard F, Wang Y, Kinzie E, Duplomb L, Godard A, Baumann H: Oncostatin M regulates the synthesis and turnover of gp130, leukemia inhibitory factor receptor alpha, and oncostatin M receptor beta by distinct mechanisms. J Biol Chem 2001, 276:47038-47045.
17. Loewen G, Reid M, Tan D, Klippenstein D, Nava E, Natarajan R, Mahoney M: Bimodality Lung Cancer Screening in High risk Patients. Chest 2004, 125:163s-164s.
18. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E: World Health Organization classification of lung and pleural tumors. Springer Verlag Berlin, Germany 1999.
19. Matsui S., Sait S, Jones CA, Nowak N, Gross KW: Rapid localization of transgenes in mouse chromosomes using a combined Spectral Karyotyping/ FISH technique. Mammalian Genome 2002, 13:680-685.
20. Tan D, Kirley S, Li Q, Ramnath R, Slocum H, Brooks J, Wu CL, Zukerberg L: Loss of Cables Protein Expression in Human Non-Small Cell Lung Cancer: A Tissue Microarray Study. Human Pathol 2003, 34:143-149.
21. Bepler G, Koehler A, Kiefer P, Havemann K, Beisenherz K, Jaques G, Gropp C. Haeder M: Characterization of the state of differentiation of six newly established human non-small-cell lung cancer cell lines. Differentiation 1988, 37:158-171.
22. Blanchard F, Kinzie E, Wang Y, Duplomb L, Godard A. Held WA, Asch BB, Baumann H: FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins. Oncogene 2002, 21: 6264-6277.
23. Douglas WG, Tracy E, Tan D, Yu J, Hicks WL Jr, Rigual NR, Loree TR, Wang Y, Baumann H: Development of head and neck squamous cell carcinoma is associated with altered cytokine responsiveness. Mol Cancer Res 2004, 2:585-593.
24. Franklin WA, Fokvord JM, Varella-Garcia M, Kennedy T, Proudfoot S, Cook R, Dempsey EC, Helm K, Bunn PA, Miller YE: Expansion of bronchial epithelial cell populations by in vitro culture of explants from dysplastic and histologically normal sites. Am J Resp Cell Mol Biol 1996, 15:297-304.
25. Blanchard F, Duplomb L, Wang Y, Robledo O, Kinzie E, Pitard V, Godard A, Jacques Y, Baumann H: Stimulation of leukemia inhibitory factor receptor degradation by extracellular signal-regulated kinase. J Biol Chem 2000, 275:28793-28801.
26. Lang R, Pauleau AL, Parganas E, Takahashi Y, Mages J, Ihle JN, Rutschman R, Murray P. J: SOCS3 regulates the plasticity of gp130 signalling. Nat Immunol 2003, 4:546-550.
27. Mahboubi K, Kirkiles-Smith NC, Karras J, Pober JS: Desensitization of signalling by oncostatin M in human vascular cells involves cytoplasmic Tyr residue 759 in gp130 but is not mediated by either Src homology 2 domain-containing tyrosine phosphatase 2 or suppressor of cytokine signalling 3. J Biol Chem 2003, 278: 25014-25023
28. Huber RM, Stratakis DF: Molecular oncology - perspectives in lung cancer. Lung Cancer 2004, 45:S209-S213.
29. Blanchard F, Tracy E, Smith J, Chattopadhyay S, Wang Y, Held WA, Baumann H: DNA methylation controls the responsiveness of hepatoma cells to leukemia inhibitory factor. Hepatology 2003, 38:1516-1528.
30. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM, Baron AE, Zeng C, Franklin WA: Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003, 21:3798-3807.
31. Clark J, Edwards S, Feber A, Flohr P, John M, Giddings I, Crossland S, Stratton MR, Wooster R, Campbell C, Cooper CS: Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays. Oncogene 2003, 22:1247-1252.
32. Morrison DK, Davis RJ: Regulation of MAP kinase signalling modules by scaffold proteins in mammals. Annu. Rev. Cell Dev. Biol. 2003, 19:91-118
33. Ramakrishna G, Sithanandam G, Cheng RY, Fornwald LW, Smith GT, Diwan BA, Anderson LM: K-ras p21 expression and activity in lung and lung tumors. Exp Lung Res 2000, 26:659-671.
34. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, Franklin RA, McCubrey AJ: Signal transduction mediated by the Ras/Raf/ MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 2003, 17:1263-1293.
35. Klausen P, Pedersen L, Jurlander J, Baumann H: Oncostatin M and interleukin 6 inhibit cell cycle progression by prevention of p27kip1 degradation in HepG2 cells. Oncogene 2000, 19: 3675-3683
36. Yu H, Jove R: The STATs of cancer-new molecular targets come of age. Nature Rev Cancer 2004, 4:97-105.
37. Lai CF, Ripperger J, Wang Y, Kim H, Hawley RB, Baumann H: The STAT3-independent signalling pathway by glycoprotein 130 in hepatic cells. J Biol Chem 1999, 274:7793-7802
38. Li C, Ahlborn TE, Kraemer FB, Liu J: Oncostatin M-induced growth inhibition and morphological changes of MDA-MB231 breast cancer cells are abolished by blocking the MEK/ERK signalling pathway. Breast Cancer Res Treat 2001, 6:111-121.